A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in <i>BRCA</i> Wild-Type, Advanced Triple-Negative Breast Cancer

Margaret E. Gatti‐Mays, Jung Min Lee, Sanaz Soltani et al.|The Oncologist|2020

Cited by 59